References
- Harnek J, James S, Lagerqvist B. Coronary Artery Perforation and Tamponade ― Incidence, Risk Factors, Predictors and Outcomes From 12 Years’ Data of the SCAAR Registry ―. Circulation Journal. 2020;84(1):43–53.
- Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med. 2015;8:43–61.
- Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K, et al. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis. 2015;242(1):102–8.
- Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. New England Journal of Medicine. 2018;379(3):215–25.
- Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics. 2020;21(12):889–97.
- Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–8.
- Zhu WY, Zhao T, Xiong XY, Li J, Wang L, Zhou Y, et al. Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia. Sci Rep. 2016;6(25478).
- Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice. 2017;2017:8062796.
- Qian W, Chen L, Zhang L, Gao M, Wang C, Qian X, et al. Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele. J Thorac Dis. 2022;14(7):2591–601.
- Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–67.
- Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary. Pharmacogenetics and Genomics. 2011;21(3):152–61.
- Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):9.
- Stokanovic D, Nikolic VN, Konstantinovic SS, Zvezdanovic JB, Lilic J, Apostolovic SR, et al. P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology. 2015;97(3–4):101–6.
- Wang X-q, Shen C-l, Wang B-n, Huang X-h, Hu Z-l, Li J. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2015;558(2):200–7.
- Hidayat R, Rasyid A, Harris S, Harahap A, Herqutanto, Louisa M, et al. Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients. Vasc Health Risk Manag. 2023;19:53–61.
- Su J, Yu Q, Zhu H, Li X, Cui H, Du W, et al. The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One. 2017;12(3).
- Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, et al. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2019;76(5):552–60.
- Adamiak-Giera U, Czerkawska A, Olędzki S, Kurzawski M, Safranow K, Jastrzębska M, et al. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention. Pharmacological Reports. 2021;73(2):583–93.
- Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. Jama. 2011;306(20):2221–8.
- Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75.
- Rossini R, Capodanno D, Musumeci G, Lettieri C, Lortkipanidze N, Romano M, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis. 2011;22(3):199–205.